LON:INDV Indivior (INDV) Share Forecast, Price & News GBX 1,590 +115.00 (+7.80%) (As of 06/5/2023 ET) Add Compare Share Share Today's Range 1,566.20▼ 1,664.7750-Day Range 1,369.60▼ 1,59052-Week Range 1,330▼ 2,020Volume573,348 shsAverage Volume417,479 shsMarket Capitalization£2.19 billionP/E RatioN/ADividend YieldN/APrice TargetGBX 2,350 ProfileProfileAnalyst RatingsChartCompetitorsInsider TradesHeadlinesProfileAnalyst RatingsChartCompetitorsInsider TradesHeadlines Indivior MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside47.2% UpsideGBX 2,340 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews Sentiment0.78Based on 4 Articles This WeekInsider TradingAcquiring Shares£2.10 M Bought Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.13 out of 5 stars 3.5 Analyst's Opinion Consensus RatingIndivior has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of GBX 2,340, Indivior has a forecasted upside of 47.2% from its current price of GBX 1,590.Amount of Analyst CoverageIndivior has only been the subject of 1 research reports in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for INDV. Previous Next 0.0 Dividend Strength Dividend YieldIndivior does not currently pay a dividend.Dividend GrowthIndivior does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for INDV. Previous Next 3.2 News and Social Media Coverage News SentimentIndivior has a news sentiment score of 0.78. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Indivior this week, compared to 1 article on an average week.MarketBeat Follows1 people have added Indivior to their MarketBeat watchlist in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Indivior insiders have bought more of their company's stock than they have sold. Specifically, they have bought £21,028 in company stock and sold GBX 0 in company stock.Percentage Held by InsidersOnly 0.68% of the stock of Indivior is held by insiders.Percentage Held by Institutions73.04% of the stock of Indivior is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Indivior is -5,678.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Indivior is -5,678.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioDue to a projected decrease in earnings for Indivior, their PEG ratio cannot be calculated.Price to Book Value per Share RatioIndivior has a P/B Ratio of 30.58. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Indivior (LON:INDV) StockIndivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders. The company's product pipeline focuses on treating opioid use disorder, addiction, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet, as well as sells legacy products that include Temgesic, Burpex, and Buprenex. The company operates in approximately 40 countries worldwide. Indivior PLC has research collaboration agreement with Addex Therapeutics Ltd. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.Read More Receive INDV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Indivior and its competitors with MarketBeat's FREE daily newsletter. Email Address INDV Stock News HeadlinesJune 5, 2023 | reuters.comIndivior opioid settlement makes purer M&A caseJune 3, 2023 | msn.comUS drugmaker Indivior to pay $102.5 million to settle Suboxone monopoly claimsJune 6, 2023 | Behind the Markets (Ad)The single greatest medical breakthrough of all time?We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.June 2, 2023 | finanznachrichten.deIndivior PLC: Indivior Reaches Agreement with States' Attorneys General and District of Columbia to Resolve Antitrust Multi-District Litigation ClaimsMay 25, 2023 | uk.finance.yahoo.comINDV.L - Indivior PLCMay 25, 2023 | finance.yahoo.comIndivior To Participate In Upcoming Investor ConferencesMay 23, 2023 | finance.yahoo.comIndivior PLC Form 20-F Registration Statement for Additional US Listing Now Available; Trading on NASDAQ Expected to Commence on June 12thMay 22, 2023 | markets.businessinsider.comFDA Approves Opiant's Nasal Spray 'Opvee' To Reverse Opioid OverdoseJune 6, 2023 | Behind the Markets (Ad)U.S. Loses to China in Shocking WAR GAMES=== BREAKING === U.S. Loses to China in Shocking WAR GAMES Pentagon says new "living missile" key to winning a future conflict. Investors stand to reap 35,960% on shares of the small defense contractor that makes powerful new weapon. Get the name of the stock here >>>May 22, 2023 | reuters.comUS FDA approves Opiant's spray for reversing opioid-related overdosesMay 22, 2023 | finance.yahoo.comIndivior Announces U.S. Food and Drug Administration Approval of OPVEE® (nalmefene) Nasal Spray, An Opioid Overdose Rescue Medicine for Natural and Synthetic Opioids Like FentanylApril 27, 2023 | finance.yahoo.comIndivior Announces Q1 2023 Financial ResultsApril 25, 2023 | finance.yahoo.comIndivior To Participate In Bank of America Global Healthcare Conference 2023March 2, 2023 | finance.yahoo.comIndivior Completes Acquisition of Opiant Pharmaceuticals, Inc.February 16, 2023 | finance.yahoo.comFY 2022 Financial Results AnnouncedFebruary 6, 2023 | finance.yahoo.comOpiant Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Proposed Acquisition by Indivior PLCJanuary 2, 2023 | finance.yahoo.comInvesting in Indivior (LON:INDV) three years ago would have delivered you a 861% gainDecember 9, 2022 | finance.yahoo.comShould You Be Excited About Indivior PLC's (LON:INDV) 73% Return On Equity?December 7, 2022 | finance.yahoo.comIndivior Capital Markets Day Highlights Strategy for Shareholder Value Creation and Attractive Medium-Term Profitable Growth OutlookNovember 14, 2022 | finance.yahoo.comIndivior To Acquire Opiant PharmaceuticalsNovember 8, 2022 | finance.yahoo.comIndivior Third Quarter 2022 Earnings: EPS: US$0.29 (vs US$0.18 in 3Q 2021)October 27, 2022 | finance.yahoo.comIndivior Announces Q3 2022 Financial ResultsOctober 11, 2022 | finance.yahoo.comIndivior PLC (LON:INDV) is favoured by institutional owners who hold 86% of the companySeptember 30, 2022 | finance.yahoo.comIndivior Shareholders Approve Resolutions to Proceed with Additional U.S. ListingSeptember 27, 2022 | businesswire.comAelis Farma: Availability of the 2022 Half-year Financial Report - Business WireSeptember 26, 2022 | law360.comTwo Funds Seek Invidior Antitrust Docs In Securities Case - Law360September 7, 2022 | finance.yahoo.comIndivior To Participate in Upcoming Investor Healthcare EventsSee More Headlines INDV Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Industry, Sector and Symbol Stock ExchangeLON Industry Drugs - Generic Sub-IndustryN/A SectorMedical Current SymbolLON:INDV CUSIPN/A CIKN/A Webindivior.com Phone+44-1753-217800FaxN/AEmployees885Year FoundedN/APrice Target and Rating Average Stock Price ForecastGBX 2,340 High Stock Price ForecastGBX 2,350 Low Stock Price ForecastGBX 2,330 Forecasted Upside/Downside+47.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)GBX (0.28) Trailing P/E RatioN/A Forward P/E Ratio1,500.00 P/E Growth-5.57Net Income£-50,000,000.00 Net Margins-5.28% Pretax MarginN/A Return on Equity-32.90% Return on Assets8.23% Debt Debt-to-Equity Ratio387.50 Current Ratio1.08 Quick Ratio1.52 Sales & Book Value Annual Sales£947 million Price / Sales2.31 Cash FlowGBX 593.26 per share Price / Cash Flow2.68 Book ValueGBX 52 per share Price / Book30.58Miscellaneous Outstanding Shares137,880,000Free FloatN/AMarket Cap£2.19 billion OptionableNot Optionable Beta-0.06 Key ExecutivesMr. Mark CrossleyCEO & Exec. DirectorMr. Ryan PreblickCFO & Exec. DirectorDr. Christian HeidbrederChief Scientific OfficerMr. Jason ThompsonVP of Investor RelationsMs. Cynthia CetaniChief Integrity & Compliance OfficerMr. Jeffrey W. Burris (Age 51)Chief Legal Officer Mr. Jon FogleChief HR OfficerMr. Richard SimkinChief Commercial & Strategy OfficerMr. Hillel WestChief Manufacturing & Supply OfficerMs. Nina DeLorenzoChief Global Impact OfficerMore ExecutivesKey CompetitorsOxford Nanopore TechnologiesLON:ONTGenusLON:GNSUDG HealthcareLON:UDGClinigen GroupLON:CLINAbcamLON:ABCView All CompetitorsInsidersMark StejbachBought 1,400 shares on 3/6/2023Total: £2.10 M ($1,502.00/share)View All Insider Transactions INDV Stock - Frequently Asked Questions Should I buy or sell Indivior stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Indivior in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" INDV shares. View INDV analyst ratings or view top-rated stocks. What is Indivior's stock price forecast for 2023? 2 Wall Street research analysts have issued twelve-month target prices for Indivior's stock. Their INDV share price forecasts range from GBX 2,330 to GBX 2,350. On average, they expect the company's share price to reach GBX 2,340 in the next twelve months. This suggests a possible upside of 47.2% from the stock's current price. View analysts price targets for INDV or view top-rated stocks among Wall Street analysts. How have INDV shares performed in 2023? Indivior's stock was trading at GBX 1,852 at the start of the year. Since then, INDV stock has decreased by 14.1% and is now trading at GBX 1,590. View the best growth stocks for 2023 here. What other stocks do shareholders of Indivior own? Based on aggregate information from My MarketBeat watchlists, some companies that other Indivior investors own include Bigblu Broadband (BBB), Futura Medical (FUM), Directa Plus (DCTA), Lakehouse (LAKE), Aquila Services Group (AQSG), Benchmark (BMK), Bodycote (BOY), CityFibre Infrastructure (CITY), Deltex Medical Group (DEMG) and Kingfisher (KGF). What is Indivior's stock symbol? Indivior trades on the London Stock Exchange (LON) under the ticker symbol "INDV." How do I buy shares of Indivior? Shares of INDV stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. What is Indivior's stock price today? One share of INDV stock can currently be purchased for approximately GBX 1,590. How much money does Indivior make? Indivior (LON:INDV) has a market capitalization of £2.19 billion and generates £947 million in revenue each year. The specialty pharmaceutical company earns £-50,000,000.00 in net income (profit) each year or GBX (0.28) on an earnings per share basis. How many employees does Indivior have? The company employs 885 workers across the globe. How can I contact Indivior? Indivior's mailing address is 103-105 Bath Road, SLOUGH, SL1 3UH, United Kingdom. The official website for the company is indivior.com. The specialty pharmaceutical company can be reached via phone at +44-1753-217800. This page (LON:INDV) was last updated on 6/6/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Indivior PLC Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.